Molecular-targeted agents from bench to bedside: Erlotinib attenuates bevacizumab-mediated activation of EGFR-survival signaling in colorectal cancer (CRC) models independent of KRAS status providing a rational basis for the DREAM phase III clinical trial

Larsen Annette K.; Muller Delphine; Bouygues Anais; Savina Ariel; de Gramont Aimery; Mesange Paul

首页> 外文期刊>International journal of molecular medicine >Molecular-targeted agents from bench to bedside: Erlotinib attenuates bevacizumab-mediated activation of EGFR-survival signaling in colorectal cancer (CRC) models independent of KRAS status providing a rational basis for the DREAM phase III clinical trial

【24h】

Molecular-targeted agents from bench to bedside: Erlotinib attenuates bevacizumab-mediated activation of EGFR-survival signaling in colorectal cancer (CRC) models independent of KRAS status providing a rational basis for the DREAM phase III clinical trial

机译：从台式到床旁的分子靶向药物：厄洛替尼减弱贝伐单抗介导的大肠癌（CRC）模型中EGFR生存信号的活化，而与KRAS状态无关，这为DREAM III期临床试验提供了合理的基础

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《International journal of molecular medicine》 |2015年第1期|共1页
作者
Larsen Annette K.; Muller Delphine; Bouygues Anais; Savina Ariel; de Gramont Aimery; Mesange Paul;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词

相似文献

外文文献

1. Molecular-targeted agents from bench to bedside: Erlotinib attenuates bevacizumab-mediated activation of EGFR-survival signaling in colorectal cancer (CRC) models independent of KRAS status providing a rational basis for the DREAM phase III clinical trial [J] . Larsen Annette K., Muller Delphine, Bouygues Anais, International journal of molecular medicine . 2015,第Suppla1期

机译：从台式到床旁的分子靶向药物：厄洛替尼减弱贝伐单抗介导的大肠癌（CRC）模型中EGFR生存信号的活化，而与KRAS状态无关，这为DREAM III期临床试验提供了合理的基础
2. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. [J] . Hurwitz HI, Yi J, Ince W, The oncologist . 2009,第1期

机译：贝伐单抗在转移性结直肠癌中的临床获益与K-ras突变状态无关：贝伐单抗联合化疗治疗未经治疗的转移性结直肠癌的III期研究的分析。
3. Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. [J] . Price TJ, Hardingham JE, Lee CK, Journal of Clinical Oncology . 2011,第19期

机译：KRAS和BRAF基因突变状态对单独的卡培他滨III期AGITG MAX试验或与贝伐单抗和丝裂霉素联用治疗晚期大肠癌的结果的影响。
4. Activated cMET and IGF1R-Driven PI3K Signaling Predicts Poor Survival in Colorectal Cancers Independent of KRAS Mutational Status [O] . Jeeyun Lee, Anjali Jain, Phillip Kim, -1

机译：活化的cMET和IGF1R驱动的PI3K信号传导可预测结直肠癌的不良生存而与KRAS突变状态无关
5. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status. [O] . Jeeyun Lee, Anjali Jain, Phillip Kim, 2014

机译：活化的cmET和IGF1R驱动的pI3K信号传导预测结肠直肠癌的存活率较低，与KRas突变状态无关。

Molecular-targeted agents from bench to bedside: Erlotinib attenuates bevacizumab-mediated activation of EGFR-survival signaling in colorectal cancer (CRC) models independent of KRAS status providing a rational basis for the DREAM phase III clinical trial

著录项

相似文献

相关主题

期刊订阅